---
schema_version: "secwatch.filing_event.v1"
accession: "0001555280-24-000295"
form_type: "8-K"
ticker: "ZTS"
cik: "0001555280"
company_name: "Zoetis Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:15:34.171068+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zoetis Q2 2024: revenue $2.4B (+11% op), adj EPS $1.56 (+20% op), raises FY guidance

## Summary
- Revenue $2.4B, +8% reported / +11% operational; U.S. +12%, International +10% op.
- GAAP net income $624M (-7%), diluted EPS $1.37 (-6%).
- Adjusted net income $711M (+9% reported, +18% operational), adjusted diluted EPS $1.56 (+11% reported, +20% operational).
- FY2024 guidance raised: revenue $9.100-9.250B, adj EPS $5.78-5.88; op rev growth 9-11%, op adj NI growth 13.5-15.5%.
- Growth led by mAb OA pain products Librela/Solensia, Simparica Trio, and dermatology portfolio Apoquel/Cytopoint.

## SEC filing metadata
- accession: 0001555280-24-000295
- form_type: 8-K
- ticker: ZTS
- cik: 0001555280
- company_name: Zoetis Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/0001555280-24-000295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1555280/000155528024000295/zts-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001555280-24-000295
- JSON: https://secwatch.observer/filing/0001555280-24-000295.json
- Plain text: https://secwatch.observer/filing/0001555280-24-000295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.